Table D-4. Clinician administered PTSD scales

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Akuchekian et al., 20041 | CAPS Mean (SD) G1 Pre-tx: 50.70 (7.7) G1 Post-tx: 32.75 (8.2)  G2 Pre-tx: 48.9 (9.13) G2 Post-tx: 46.62 (8.8)  G1 vs. G2, p=0.00 (based on t-test) | NR | NR | NR |
| Asukai et al., 20102 | CAPS Adjusted Mean (SE)  G1 Pre-tx:84.58 (7.78)  G1 Post-tx: 43.76 (8.43)  G2 Pre-tx:84.33 (7.78)  G2 Post-tx: 84.81 (7.96)  At post: G1 vs. G2=  p<0.01(based on t-test) | NR | NR | NR |
| Bartzokis et al., 20053 | CAPS Unadjusted Change from baseline (SD) G1: -14.3 (16.7) G2: -4.6 (13.2)  G1 vs. G2, p<0.05 | NR | NR | NR |
| Basoglu et al., 20074 | CAPS Mean (SD) G1 Pre-tx: 63.1 (10.1) G1 Week 4: 38.7 (18.7) G1 Week 8:30.2 (20.3)   G2 Pre-tx: 62.3 (14.5) G2 Week 4: 54.5 (16.9) G2 Week 8: 49.1 (20.3)  G1 vs. G2 at Week 4, p<0.01  G1 vs. G2 at Week 8, p<0.01 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Becker et al., 20075 | CAPS  Within Group Mean Change (SD)(Baseline-Endpoint) G1: 12.33 (24.12)  G2: 16.99 (11.26)  Group effect , p<0.01 | NR | NR | NR |
| Blanchard et al., 20036 | CAPS  Mean (SD)  G1 Pre-tx: 68.2 (22.7)  G1 Post-tx: 23.7 (26.2)  G2 Pre-tx: 65.0 (25.9)  G2 Post-tx:40.1 (25.7)  G3 Baseline: 65.8 (26.6)  G3 Post-tx: 54.0 (25.9)  Group X Time at post-tx, p<0.001  G1 vs. G2, p=0.002  G1 vs. G3, p<0.001  G2 vs. G3, p=0.012  Including Dropouts  Group X Time at post-tx, p<0.001  G1 vs. G2, p=0.013  G1 vs. G3, p<0.001  G2 vs. G3, p=0.052  Group X Time, 3 mth FU  p=0.048  G1 continued to have lower scores than G2, p=0.003  Decreases from post-tx to the 3 mth fu, NS | NR | NR | NR |
| Boden et al., 20127 | NR | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Brady et al., 20008 | CAPS-2  Mean change (SEM) G1: -33.0 (2.8) G2: -23.2 (2.9) Difference Between Mean Change (95% CI): 9.8 (1.8 to 17.7), p=0.02 | NR | NR | NR |
| Brady et al., 20059 | CAPS ANCOVA F (2, 68) = 2.68, p=0.08 | NR | NR | NR |
| Bryant et al., 200310 | CAPS-Intensity Mean (SD) G1 Pre-tx: 32.50 (8.71)  G1 Post-tx: 19.15 (11.15) G1 6 mth FU: -20.70 (12.00)  G2 Pre-tx: 32.70 (7.51)  G2 Post-tx: 15.90 (13.36) G2 6 mth FU: 15.70 (14.79)  G3 Pre-tx: 32.83 (8.01)  G3 Post-tx: 28.00 (15.31) G3 6 mth FU: 30.28 (12.89)  Post-tx, p<0.01 (main effects)  FU, p<0.05 (main effects) | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Bryant et al., 200310 cont’d | CAPS-Frequency (CAPS-F) Mean (SD) G1 Pre-tx: 36.80 (9.82)  G2 Post-tx: 20.55 (12.73) G1 6 mth FU: 23.25 (12.90)  G2 Pre-tx: 36.00 (8.69)  G2 Post-tx:17.20 (15.62) G2 6 mth FU: 17.00 (15.22)  G3 Pre-tx: 38.33 (9.64)  G3 Post-tx: 30.00 (16.42) G3 6 mth FU: 32.44 (13.57)  Post-tx, p<0.01 (main effects)  FU, p<0.05 (main effects) |  |  |  |
| Bryant et al., 200811 | CAPS Mean (SD) G1 Pre-tx: 73.29 (18.82)  G1 Post-tx: 55.50 (33.83)  G1 6 mth FU: 59.94 (32.36)  G2 Pre-tx: 76.79 (15.53)  G2 Post-tx: 55.96 (24.56)  G2 6 mth FU: 59.32 (29.62)  G3 Pre-tx: 76.06 (19.19)  G3 Post-tx: 55.39 (37.45)  G3 6 mth FU: 56.39 (35.87)  G4 Pre-tx: 71.35 (17.28)  G4 Post-tx: 29.86 (27.11) G4 6 mth FU: 32.86 (27.44)  Post-tx, p<0.01 (main effect)  6 mth FU, p<0.005 (main effect) | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Butterfield et al., 200112 | NR | NR | SIP  Mean (SD) G1 Pre-tx: 39.7 (9.7) G1 Post-tx: 19.2 (8.7)  G2 Pre-tx: 45.9 (8.2) G2 Post-tx: 17.0 (17.5) | TOP-8  Mean (SD) G1 Pre-tx: 19.3 (4.2) G1 Post-tx: 12.6 (6.4)  G2Baseline: 21.8 (3.3) G2 Post-tx: 10.5 (8.7)  SPRINT - Mean (SD) G1 Pre-tx: 31.5 (5.7) G2 Post-tx: 17.9 (7.8)  G2 Pre-tx: 34.8 (2.1) G2 Post-tx: 20.5 (11.1) |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Carlson et al., 199813 | CAPS - Frequency  Mean (SD) G1 Pre-tx: 2.5 (0.5)  G1 3 mth FU: 0.7 (0.6)  G2 Pre-tx: 2.6 (0.5)  G2 3 mth FU: 2.0 (0.7)  G3 Pre-tx: 2.4 (0.6)  NR  Group X Time, p<0.0004  CAPS Total - Intensity: Mean(SD) G1 Pre-tx: 2.4 (0.7)  G1 3 mth FU: 0.8 (0.7)  G2 Pre-tx: 2.4 (0.5)  G2 3 mth FU: 2.0 (0.5)  G3 Pre-tx: 2.5 (0.6)  NR  Group X Time, p<0.002  CAPS Total - Overall Mean Change (SD) at 9 months G1: 36.9 (28.6) G2: 67.8 (24.7) p<0.05 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Chard et al., 200514 | CAPS-SX G1 Pre-tx: 65.46 (26.39) G1 Post-tx: 9.00 (11.04)  G2 Pre-tx 68.30 (23.67) G2 Post-tx: 62.96 (30.68)  p<0.001 (interaction) | NR | NR | NR |
| Cloitre et al., 200215 | CAPS  Mean (SD) G1 Pre-tx:69 (16.3)  G1 Post-tx: 31 (25.2)  G2 Pre-tx:69 (16.6)  G2 Post-tx:62 (22.7)  p<.01 (interaction) | NR | NR | NR |
| Cloitre et al., 201016 | CAPS Mean (SD) G1 Pre-tx:63.08 (18.29)  G1 Post-tx: 32.70 (19.37)  G1 3 mth FU:24.66 (18.47)  G1 6 mth FU:20.44 (19.01)  G2 Pre-tx: 64.34 (21.15)  G2 Post-tx: 32.32 (23.04)  G2 3 mth FU:31.88 (22.98)  G2 6 mth FU:32.51 (22.69)  G3 Pre-tx: 64.50 (15.86) G3 Post-tx: 39.72 (18.34)  G3 3 mth FU: 39.71 (17.59)  G3 6 mth FU: 28.56 (21.00)  Group X Time  G1 vs. G3 at 3 mths, p=0.01  No other contrasts significant | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Connor et al., 199917  Meltzer-Brody et al., 200018 | NR | NR | SIP Week 12 difference (Baseline - Endpoint) (95% CI) G1 vs. G2 Difference: 10.3 (3.7 to 16.9), p<0.005  According to Meltzer-Brody paper, effect was significant for all 4 cluster scores (p<0.02) (intrusion, avoidance, numbing, hyperarousal) | Duke Global Severity Rating for PTSD (Duke) Week 12 difference (Baseline - Endpoint) (95% CI) G1 vs. G2 Difference: 1.1 (0.6 to 1.6), p<0.0001 |
| Cook et al., 201019 | CAPS Mean (SD) G1 Pre-tx: 81.34 (14.00) G1 Post-tx: 74.04 (20.36)  G2 Pre-tx: 79.48 (15.27) G2 Post-tx:74.85 (19.52)  p<0.001 (treatment effect, Wald) | NR | NR | NR |
| Cottraux, 200820 | NR | NR | NR | NR |
| Davidson et al., 200121 | CAPS-2  Change from Baseline to Endpoint (SD) G1: -33.0 (2.4) G2: -26.2 (2.3) p=0.04 (t-test) | NR | NR | NR |
| Davidson et al., 200322 | NR | NR | SIP  Mean (SD)  G1 Pre-tx:34.7 (7.0)  G1 Post-tx:17.4 (4.0)  G2 Pre-tx:38.4 (6.7)  G2 Post-tx:32.9 (12.7)  Between Tx effect size 1.06 p=0.04  Treatment effect F=5.0; p=.04) | SPRINT  Mean (SD)  G1 Pre-tx:21.7 (6.0)  G1 Post-tx:12.4 (8.8)  G2 Pre-tx:25.0 (4.2)  G2 Post-tx: 19.4 (8.2) Between Tx effect size 0.49  p=NS  Treatment effect, F=1.7; p=.20 |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Davidson et al., 200623 | CAPS-SX17  Mean Within-group difference (95% CI): G1: -41.51 (-45.66 to -37.36)  G2: -39.44 (-43.67 to - 35.21) G3: -34.17 (-38.33 to -30.01)  Between group p-values based on pairwise comparisons from the analysis of covariance model using baseline adjusted values G1 vs. G3: 0.015 G2 vs. G3: 0.081 G1 vs. G2: 0.494 | NR | NR | NR |
| Davidson et al., 200624 | CAPS-SX  Mean (SD) G1 Pre-tx: 81.0 (14.62) G1 Post-tx: 29.2 (26.09)  G2 Pre-tx: 82.9 (15.50) G2 Post-tx: 38.1 (29.11)  Between Group Mean Difference  -8.9, p=0.006 | NR | NR | NR |
| Davidson et al., 200725 | CAPS  Change from baseline (SD)  G1: 30.7 (25.1) G2: 30.2 (26.3) p=0.85 | NR | NR | DTS & TOP-8 NR, both NS |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Davis et al., 200826 | CAPS  Mean(SD) G1 Pre-tx: 75.2 (19.1)  G1 Post-tx: 60.1 (24.1)  G2 Pre-tx: 77.3 (15.3) G2 Post-tx: 60.8 (26.6)  30% reduction in PTSD scores: G1: NR G2: NR Diff b/t groups, p>0.45  G1 vs. G2, diff over time, p=NS | NR | NR | TOP-8  Mean(SD)  G1 Pre-tx: 19.4 (5.3)  G1 Post-tx: 15.4 (6.6)  G2 Pre-tx: 19.7 (4.3)  G2 Post-tx: 15.8 (6.5)  G1 vs. G2, NS |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Ehlers et al., 200327 | CAPS Frequency  Mean (SD)  G1 Pre-tx: 31.7 (9.5)  G1 3 mth FU: 11.2(10.3)  G1 9 mth FU: 10.2 (9.9)  G2 Pre-tx: 32.6 (8.6)  G2 3 mth FU: 22.9 (12.9)  G2 9 mth FU: 21.4 (11.4)  G3 Pre-tx: 32.8 (11.5)  G3 3 mth FU: 25.6 (12.9)  G3 9 mth FU: 21.1 (15.2)  3 mth FU  Overall: p<0.001  G1 vs. G2, p<0.001  G1 vs. G3, p<0.001  9 mth FU  Overall: p<0.001  G1 vs. G2: p<0.001  G1 vs. G3: p=0.001  CAPS Intensity  Mean (SD)  G1 Pre-tx: 26.7 (7.4) G1 3 mth FU: 10.2 (9.4)  G1 9 mth FU: 9.7 (9.5)  G2 Pre-tx: 26.7 (7.4)  G2 3 mth FU: 19.6 (9.0)  18.6 (10.1)  G2 9 mth FU: G3: 22.4 (11.9) | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Ehlers et al., 200327  (continued) | G3 Pre-tx: 25.9 (10.4)  G3 3 mth FU: 22.4 (11.9)  G3 9 mth FU: 17.0 (13.8)  3 mth FU  Overall: p <0.001  G1 vs.G2: p<0.001  G1 vs. G3: p<0.001  9 mth FU Overall, p=0.002  G1 vs.G2, p=0.001  G1 vs. G3, p=0.004 |  |  |  |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Ehlers et al., 200528 | CAPS-Intensity  Mean (SD) G1 Pre-tx: 36.5 (9.4) G1 Post-tx: 13.7 (13.4) G1 Post-tx FU adjusted: 10.4 G1 6 mth FU: 15.5 (14.8)  G2 Pre-tx: 29.0 (8.5) G2 Post-tx: 30.9 (9.6) G2 Post-tx adjusted: 34.2  G1 vs. G2, p<0.005  Changes in G1, p<0.005  Changes in G2, NS  CAPS-Frequency  Mean (SD) G1 Pre-tx: 42.0 (8.5) G1 Post-tx: 16.0 (15.3) G1 Post-tx adjusted: 11.4 G1 6 mth FU: 16.0 (14.4)  G2 Pre-tx: 31.6 (8.4) G2 Post-tx: 35.5 (11.4) G2 Post-tx adjusted: 40.2  G1 vs. G2, p<0.005  Changes in G1, p<0.005  Changes in G2, NS | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Fecteau et al., 199929 | CAPS-2  Mean (SD) G1 Pre-tx: 70.9 (16.2)  G1 Post-tx: 37.5 (30.4)  G2 Pre-tx: 77.3 (22.7)  G2 Post-tx: 74.6 (24.7)  Group effects, p<0.01 | NR | NR | NR |
| Foa et al., 199930  Zoellner et al., 199931 | NR | PSS-I Mean (SD) G1 Pre-tx: 29.48 (9.94) G1 Post-tx: 11.70 (7.32) G1 3 mth FU: 11.84 (9.01) G1 6 mth FU: 11.16 (7.38) G1 12 mth FU: 10.69 (8.96)  G2 Pre-tx: 29.42 (8.69) G2 Post-tx: 12.89 (8.96) G2 3 mth FU: 15.06 (13.33) G2 6 mth FU: 11.24 (11.86) G2 12 mth FU: 12.64 (14.71)  G3 Pre-tx: 29.95 (6.97) G3 Post-tx: 13.55 (9.35) G3 3 mth FU:11.45 (9.03) G3 6 mth FU: 13.17 (10.98) G3 12 mth FU: 12.56 (12.25)  G4 Pre-tx 32.93 (5.89) G4 Post-tx: 26.93 (8.47)  Main Effects, p<0.01  G1 vs. G4, p<0.001  G2 vs. G4, p<0.05  G3 vs. G4, p<0.05  G1 vs. G2, p=0.14  G1 vs. G3, p=0.11 | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Foa et al., 200532 | NR | PSS-I Mean (SD) G1 Pre-tx: 34.0 (5.9) G1 Post-tx: 17.9 (14.5)  G2 Pre-tx: 31.1 (8.1) G2 Post-tx: 16.8 (13.2)  G3 Pre-tx: 33.3 (6.2) G3 Post-tx: 26.8 (9.6)  Group X Time interaction, p<0.01  G1 vs. G3 t-test, p<0.001 | NR | NR |
| Forbes et al., 201233 | CAPS  Mean (SD)  G1 Pre-tx: 75.53 (16.35)  G1 Post-tx: 48.03 (27.89)  G1 3 month FU: 45.30 (28.15)  G2 Pre-tx: 64.55 (19.46)  G2 Post-tx: 57.73 (20.01)  G2 3 month FU: 52.55 (18.93)  Change over time  Post-tx, p=0.002  Post vs. 3 month FU, p=0.649 | NR | NR | NR |
| Ford et al., 201134 | CAPS  Mean (SD)  G1 Pre-tx: 62.3 (18.1)  G1 Post-tx:38.7 (25.6)  G2 Pre-tx: 61.9 (21.3)  G2 Post-tx: 39.7 (21.4)  G3 Pre-tx: 68.7 (17.0)  G3 Post-tx: 62.5 (23.3)  Group X Time Effect, p<0.001 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Friedman et al., 200735 | CAPS-2 Change at Endpoint (SE)  G1: -13.1(3.0)  G2: -15.4(3.1)  Between Group Differences, NS | NR | NR | NR |
| Gamito et al., 201036 | CAPS G1 Percentage variation: -8 G2 Percentage variation: -1 G3 Percentage variation: -6  Effects, NS | NR | NR | NR |
| Gersons et al., 200037 | NR | NR | NR | NR |
| Hamner et al., 200338 | CAPS  Mean (SD) G1 Pre-tx: 90.3 (23.0) G1 Post-tx: 81.3 (24.3)  G2 Pre-tx: 89.1 (12.2) G2 Post-tx: 79.0 (21.0)  Between-treatment changes, NS | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Hien et al., 200439 | CAPS Frequency and Intensity Mean (SD) G1 Pre-tx: 72.17 (19.70)  G1 Post-tx: 57.15 (22.33)  G1 6 mth FU: 59.85 (21.12) G1 9 mth FU: 55.34 (20.85)  G2 Pre-tx: 70.38 (16.84)  G2 Post-tx: 51.21 (25.21)  G2 6 mth FU: 52.65 (24.08) G2 9 mth FU: 47.82 (27.73)  G3 Pre-tx: 73.88 (19.16)  G3 Post-tx:68.00 (24.20)  G3 6 mth FU:64.79 (23.81) G3 9 mth FU: 66.00 (23.99)  CAPS Global Severity Mean (SD) G1 Pre-tx: 2.73 (0.63)  G1 Post-tx: 2.14 (1.53)  G1 6 mth FU:  G1 9 mth FU: 1.79 (0.63)  G2 Pre-tx: 2.41 (0.70)  G2 Post-tx:1.75 (0.79)  G2 6 mth FU: 1.62 (0.65) G2 9 mth FU: 1.40 (1.12)  G3 Pre-tx: 2.82 (1.16)  G3 Post-tx: 2.43 (1.09)  G3 6 mth FU: 2.35 (0.70) G3 9 mth FU: 2.14 (1.07)  Significance NR for CAPS | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Hien et al., 200940  Hien et al., 201241 | CAPS, ITT Analysis Data  Mean (SD) G1 Pre-tx: 61.6 (19.4)  G1 Post-tx: 31.7 (23.4)  G1 Average of FU: 24.3 (22.1)  G2 Pre-tx: 64.2 (19.4) G2 Post-tx.: 32.7 (23.4) G2 Average of FU: 27.1 (23.4)  Post-tx  G1 vs. G2, p<0.001 | NR | NR | NR |
| Hinton et al., 200542 | CAPS Mean (SD) G1 Pre-tx: 74.85 (14.67) G1 2nd Assessment: 39.25 (19.92)  G1 3rd Assessment: 41.30 (13.95)  G1 FU Assessment: 44.56 (14.58)  G2 Pre-tx: 75.91 (11.5) G2 2nd Assessment: 73.05 99.43)  G2 3rd Assessment: 45.05 (8.72)  G2 FU Assessment: 43.56 (10.22)  Group Diffferences at 2nd Assessment, p<0.001  Group Differences at 1st, 3rd, & 4th assessments, NS | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Hinton et al., 200943 | CAPS  Mean (SD) G1 Pre-tx: 75.41 (13.47) G1 2nd Assessment: 46.83 (17.17) G1 3rd Assessment: 44.75 (14.85)  G2 Pre-tx: 77.25 (11.47) G2 2nd Assessment: 74.25 (9.43) G2 3rd Assessment: 45.83 (8.45)   Between group difference at 2nd assessment , p<0.01  Between group differences at 3rd assessment, NS | NR | NR | NR |
| Hinton et al., 201144 | NR | NR | NR | NR |
| Hogberg et al., 200745 | NR | NR | NR | NR |
| Hollifield et al., 200746 | NR | NR | NR | NR |
| Johnson et al., 201147 | CAPS  Mean (SD) G1 Pre-tx: 53.34 (24.29)  G1 Post-tx: 24.76 (18.47)  G1 3 mth FU: 21.15 (24.79)  G1 6 mth FU: 18.62 (18.84)  G2 Pre-tx: 62.69 (25.38)  G2 Post-tx: 42.38 (29.33)  G2 3 mth FU: 31.27 (22.01)  G2 6 mth FU: 26.56 (25.83)   Time effect, *p<*0 .0001  Treatment effect, p>0.05 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Krakow et al., 200148 | CAPS  Mean (SD)  G1 Pre-tx: 81.88 (16.96) G1 Post-tx: 49.58 (23.96) Change: 32.3 (21.40)  G1 Pre-tx: 79.62 (24.37) G2 Post-tx: 68.37 (27.26) Change: 11.25 (21.65)  G1 vs. G2, p<0.001 | PSS  Mean (SD) G1 Pre-tx: 28.29 (10.37) G1 Post-tx: 17.19 (10.39) Change: 11.1 (11.06)  G1 Pre-tx: 28.48 (11.73) G2 Post-tx: 25.26 (11.78) Change: 3.22 (9.02)  G1 vs. G2, p<0.001 | NR | NR |
| Kruse et al., 200949 | NR | NR | NR | HTQ Mean (SD)  G1 Pre-tx: 3.5 (0.4)  G1 Post-tx: 2.2 (0.7)  G2 Pre-tx: 3.5 (0.4)  G2 Post-tx: 3.6 (0.3)  Group X Time Interaction, p<0.001  Within Group Change  G1: p<0.001  G2: p<0.05 |
| Krystal et al., 201150 | CAPS  Mean Difference (95 % CI)  2.73 (-0.74 to 6.20)  p=0.12 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Kubany et al., 200351 | CAPS  Mean (SD)  G1 Pre-tx: 80.9 (20.7)  G1 Post-tx: 10.1 (19.3)  G1 3 mth FU: 7.9 (9.3)  G2 Pre-tx: 79.1 (22.1)  G2 Post-tx: 76.1 (25.2)  G2 Post-therapy: 11.6 (13.6)  G2 3 mth FU: 12.4 (13.8)    G1 Post-tx change, p<0.05  G2 Post-tx change, NS  G1 3 mth change, NS  G2 Post-therapy, p<0.05  G2 3 mth change, NS | NR | NR | NR |
| Kubany et al., 2004{Kubany, 2004 #806) | CAPS (ITT Sample)  Mean (SD)  G1 Pre-tx:74.4 (19.9)  G1 Post-tx: 33.3 (32.8)  G2 Pre-tx: 78.0 (20.5)  G2 Post-tx: 74.1 (21.9)  Between group significance, NR | NR | NR | NR |
| Liedl et al., 201153 | NR | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Lindauer et al., 200554 | NR | NR | SI-PTSD Reexperiencing Score Mean (SD) G1 Pre-tx: 3.4 (0.9) G1 Post-tx: 1.2 (1.5)  G2 Pre-tx: 3.9 (0.8) G2 Post-tx: 3.1 (1.8)  G1 vs. G2, p<0.05  SI-PTSD Avoidance Score Mean (SD) G1 Pre-tx: 3.9 (1.1.) G1 Post-tx: 1.6 (2.2)  G2 Pre-tx: 3.5 (0.7) G2 Post-tx: 3.2 (1.7)  G1 vs. G2, NS  SI-PTSD Hyperarousal  Mean (SD) G1 Pre-tx: 3.8 (0.9) G2 Post-tx: 1.3 (1.8)  G2 Pre-tx: 3.8 (1.0) G2 Post-tx: 2.7 (1.5)  G1 vs. G2, p<0.05 | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Litz et al., 200755 | NR | PSS-I Mean (SD) (Completer Group) G1 Pre-tx: 26.71 (9.02)  G1 Post-tx: 14.86 (13.35)  G1 3 mth FU: 13.20 (8.63)  G1 6 mth FU: 8.67 (7.98)  G2 Pre-tx: 29.16 (9.93) G2 Post-tx: 20.00 (11.50) G2 3 mth FU: 13.96 (8.63) G2 6 mth FU: 17.50 (10.40)  ITT Analysis  Post-tx Time effect, p<0.001  3 mth FU  G1 v.s G2, NS  Completer Analysis 3 mth FU  G1 vs. G2, NS 6 mth FU Group Effect, p =0.06 | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Marks et al., 199856  Lovell et al., 200157 | Marks et al., 199856  CAPS-2 Mean Change Score at Post-tx (95% CI) G1: 30 (19 to 42)  G2: 36 (26 to 45) G3: 38 (26 to 50) G4: 14 (4 to 25)  Additional results presented in graphs  CAPS  Mean change in G1 + G2 + G3 vs. G4  Post, p=0.005  1 mth FU, p=0.01  3 mth FU, p=0.005  Lovell et al., 200157  CAPS, Re-experiencing subscale  Mean (SD)  G1 Pre-tx: 13.3 (3.9)  G1 Post-tx: 6.8 (7.5)  G2 Pre-tx: 14.9 (5.0)  G2 Post-tx: 7.8 (4.9)  G3 Pre-tx: 15.1 (6.4)  G3 Post-tx: 6.8 (7.2)  G4 Pre-tx: 11.6 (6.1)  G4 Post-tx: 9.7 (7.4)  Post-tx  G1 + G2 +G3 vs. G4, p<0.02  Followups  G1 + G2 +G3 vs. G4, NS | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Marks et al., 199856  Lovell et al., 200157cont’d | CAPS, Advoidance/numbing subscale  Mean (SD)  G1 Pre-tx: 23.4 (8.3)  G1 Post-tx: 11.5 (13.1)  G2 Pre-tx: 30.7 (7.6)  G2 Post-tx: 15.2 (11.0)  G3 Pre-tx: 29.8 (9.3)  G3 Post-tx: 11.9 (11.9)  G4 Pre-tx: 23.0 (9.1)  G4 Post-tx: 17.1 (8.9)  Post-tx  G1 + G2 +G3 vs. G4, p<0.004  1 month FU  G1 + G2 +G3 vs. G4, p<0.02  3 month FU  G1 + G2 +G3 vs. G4, p<0.01  CAPS, Increased arousal subscale  Mean (SD)  G1 Pre-tx: 25.2 (8.5)  G1 Post-tx: 13.2 (11.1)  G2 Pre-tx: 29.1 (8.8)  G2 Post-tx: 16.5 (10.0)  G3 Pre-tx: 28.6 (7.7)  G3 Post-tx: 16.6 (11.7)  G4 Pre-tx: 23.7 (7.6)  G4 Post-tx: 17.0 (10.5)  Post-tx  G1 + G2 +G3 vs. G4, NS |  |  |  |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Marks et al., 199856  Lovell et al., 200157cont’d | Followups  G1 + G2 +G3 vs. G4, NS  CAPS, Associated features subscale  Mean (SD)  G1 Pre-tx: 16.7 (9.0)  G1 Post-tx: 8.1 (9.7)  G2 Pre-tx: 22.6 (10.2)  G2 Post-tx: 10.3 (8.8)  G3 Pre-tx: 20.8 (10.8)  G3 Post-tx: 11.0 (11.0)  G4 Pre-tx: 15.2 (8.0)  G4 Post-tx: 12.0 (11.0)  Post-tx  G1 + G2 +G3 vs. G4, p<0.04  Followups  G1 + G2 +G3 vs. G4, NS |  |  |  |
| Marshall et al., 200158 | CAPS-2 Adjusted Mean Differences (95% CI) G1 vs. G3 -14.3 (-19.7 to -8.8)  p<0.001  G2 vs. G3 -12.2 (-17.7 to -6.6)  p<0.001 | NR | NR | TOP-8 Adjusted Mean Differences (95% CI) G1 vs. G3 -3.4 (-5.1 to -1.8)  p<0.001  G2 vs. G3 -2.9 (-4.5 to -1.3)  p<0.001 |
| Martenyi et al., 200259  Martenyi et al., 200660 | CAPS Changes from Pre-tx to Post-tx Least Square Means (SD), p-value G1: -34.6 (28.1) G2: -26.8 (26.1) p=0.021 | NR | NR | TOP-8  Changes from Pre-tx to Post-tx Least Square Means, p-value G1: -10.3 G2: -8.0 p=0.006 |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Martenyi et al., 200761 | CAPS  Mean change from baseline (SD)  ITT Analysis G1: -42.9 (23.1) G2: -42.8 (27.9) G3: -36.6 (25.7)  Overall p-value= 0.15 | NR | NR | TOP-8  Mean change from baseline (SE)  Completer analysis  G1: -10.59 (0.58) G2: -10.25 (0.60) G3: -10.59 (0.81) Overall p-value= 0.907 |
| McDonagh et al., 200562 | CAPS Mean (SD) G1 Pre-tx: 69.9 (16.8) G1 Post-tx: 53.1 (28.8)  G2 Pre-tx: 67.7 (14.6) G2 Post-tx: 47.2 (22.4)  G3 Pre-tx: 72.0 (17.6) G3 Post-tx: 65.5 (18.6)  Group X Time, p<0.10 | NR | NR | NR |
| Monnelly et al., 200363 | NR | NR | NR | NR |
| Monson et al., 200664 | CAPS Mean (SE) G1 Pre-tx: 76.73 (2.6) G1 Post-tx: 52.14 (3.9) G1 1 mth FU: 58.13 (4.5)  G2 Pre-tx: 79.10 (3.5) G2 Post-tx: 76.03 (3.7) G1 1 mth FU: 74.37 (4.3)  Group X Time, p<0.01 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Mueser et al., 200865 | CAPS  Mean (SD) G1 Pre-tx: 74.46 (17.56) G1 Post-tx: 55.53 (27.92) G1 3 mth FU: 55.10 (25.96) G1 6 mth FU: 57.48 (25.34)  G2 Pre-tx: 76.15 (17.07) G2 Post-tx: 67.78 (26.84) G2 3 mth FU: 64.80 (28.25) G2 6 mth FU: 70.90 (24.15)  Group effect, p=0.005 | NR | NR | NR |
| Nacasch et al., 201166 | NR | PSS-I  Mean (SD)  G1 Pre-tx: 37.1 (3.8)  G1 Post-tx: 18.9 (9.1)  G1 FU: 16.3 (10.4)  G2 Pre-tx: 36.8 (6.2)  G2 Post-tx: 35.0 (8.9)  G2 FU: 35.4 (7.6)  Post-tx  Treatment X Time, p<0.001  12 month FU  Treatment X Time (Pre to FU), p<0.001  Treatment X Time (Post to FU), NS | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Neuner et al., 200467 | NR | NR | NR | Composite International Diagnostic Interview-PTSD Mean (SD) G1 Pre-tx: 13.4 (2.1) G1 1 year FU: 8.9 (2.7)  G2 Pre-tx: 13.9 (2.3) G2 1 year FU: 12.6 (3.2)  G3 Pre-tx: 14.2 (2.9) G3 1 year FU: 13.4 (3.3)  1 year Group X Time  G1 vs. G2, p=0.01  G1 vs. G3, p=0.01 |
| Neuner et al., 200868 | NR | NR | NR | PDS Mean (SD) G1 Pre-tx: 25.9 (13.2)  G1 Post-tx: 5.4 (6.6) G1 6 mth FU: 6.1 (6.8)  G2 Pre-tx: 26.7 (12.5)  G2 Post-tx: 5.3 (5.7) G2 6 mth FU: 5.0 (6.6)  G3 Pre-tx: 21.3 (10.6) G3 Post-tx: NR  G3 6 mth FU: 10.1 (8.1)  G1 vs. G2 Comparisons  Group X Time at Post-tx, p=0.87  Treatment Groups vs. Control  Treatment X Time, p=0.01 |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Neuner et al., 201069 | NR | NR | NR | PDS Mean(SD) G1 Pre-tx: 38.9 (6.4) G1 Post-tx: 26.0 (9.2)  G2 Pre-tx: 36.9 (8.0) G2 Post-tx: 34.1 (6.1)  Group X Time, p=0.01 |
| Nijdam et al., 201270 | NR | NR | SI-PTSD  Mean Difference at 1st Post (95% CI)  10.80 (6.37 to 15.23)  p<0.001  Mean Difference at 2nd Post (95% CI)  2.41 (-2.10 to 6.92)  p=0.29 | NR |
| Panahi et al., 201171 | NR | NR | NR | NR |
| Petrakis et al., 201172 | CAPS Mean( SE) G1 Pre-tx: 73.54 (5.007) G1 Post-tx: 40.024 (5.53)  G2 Pre-tx: 69.810 (5.166) G2 Post-tx: 36.591 (5.570)  G3 Pre-tx: 62.500 (5.047) G3 Post-tx: 26.751 (5.353)  G4 Pre-tx: 77.833 (4.832) G4 Post-tx: 41.392 (4.949)  Time effect, p<0.00  Group X Time, NS | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Raskind et al., 200373 | CAPS  G1 Pre-tx:79.1 (17.0) G1 Post-tx: 57.3 (32.3)  G2 Pre-tx: 83.6 (17.6) G2 Post-tx: 86.5 (30.0)  G1 vs. G2 Change, p<0.01 | NR | NR | NR |
| Raskind et al., 200774 | CAPS  Means (SD) G1 Pre-tx: 76.0 (22) G1 Post-tx: 63.0 (20.0)  G2 Pre-tx: 78.0 (18.0) G2 Post-tx: 71.0 (22.0)  G1 vs. G2 Change, NS | NR | NR | NR |
| Reich et al., 200475 | CAPS-2 Mean Changes from Baseline Score (SD) G1: -29.6 (31.5) G2: -18.6 (12.3) p=0.015 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Resick et al., 200276  Resick et al., 200377 Resick et al., 201278 | CAPS  Mean (SD)  G1 Pre-tx: 74.76 (18.77)  G1 Post-tx: 39.08 (31.12)  G1 3 mth FU: 42.21 (30.13  G1 9 mth FU: 42.87 (31.06)  G1 LTFU: 26.00 (23.35)  G2 Pre-tx:76.60 (19.72)  G2 Post-tx: 44.89 (33.52)  G2 3 mth FU: 49.16 (32.86)  G2 9 mth FU: 46.98 (33.68)  G2 LTFU: 25.90 (26.05)G3 Pre-tx: 69.85 (19.57)  G3 Post-tx: 69.26 (18.55)  G3 3 mth FU: 69.26 (18.55)  G3 9 mth FU: 69.26 (18.55)Posttreatment differences, p<.0001  3 mth FU differences, p<0.0001  9 mth FU differences, p<0.0001  LTFU differences, NS | NR | NR | NR |
| Rothbaum et al., 199779 | NR | PSS Mean (SD) G1 Pre-tx: 33.3 (8.7) G1 Post-tx: 14.3 (8.4) G1 3 mth FU: 9.8 (8.7)  G2 Pre-tx: 39.0 (8.2) G2 Post-tx: 35.0 (5.9)  Posttreatment G1 vs. G2, p<0.05 | NR | NR |
| Rothbaum et al., 200580 | Data reported in graphs | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Rothbaum et al., 200681 | NR | NR | SIP  Mean Change from Baseline (SD)  G1: -0.3 (7.60)  p=ns  G2: 5.9 (7.82)  p<0.001  G1 vs. G2, ns (t-test) | NR |
| Schneier et al., 201282 | CAPS  Mean (SD) G1 Pre-tx: 72.6 (12.9)  G1 Post-tx: 21.5 (19.9)  G2 Pre-tx: 65.4 (12.8) G2 Post-tx: 35.6 (31.3)  Treatment Group Effect, p=0.01 Time Effect, p<0.001 | NR | NR | NR |
| Schnurr et al., 200383 | CAPS  Mean (SE) G1 Pre-tx: 80.41 (1.45) G1 7 mth FU: 74.00 (1.32) G1 12 mth FU: 72.79 (1.51) Change at 7 mths, p<0.001  Change at 12 mths, p<0.001  G2 Pre-tx: 82.01 (1.44) G2 7 mth FU: 76.03 (1.32) G2 12 mth: 74.82 (1.49) Change at 7 mths, p<0.001  Change at 12 mths, p<0.001  Treatment Effect, p=0.29  Cohort Effect, p=0.01  Treatment X Cohort Effect, p=0.04 | NR | NR | PTSD Checklist Mean (SD) G1 Pre-tx: 61.84 (0.91) G1 7 mth FU: 59.70 (0.84) G1 12 mth FU: 58.78 (0.89) Change at 7 mths, p<0.01  Change at 12 mths, p<0.01  G2 Pre-tx: 62.60 (0.94) G2 7 mth FU: 61.03 (0.84) G2 12 mth FU: 60.00 (0.88) Change at 7 mths, p>0.05  Change at 12 mths, p<0.05  Treatment Effect, NS  Treatment X Cohort Effect, p=0.05 |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Schnurr et al., 200784 | CAPS  Baseline  Mean (95% CI)  G1: 77.6 (74.8 to 80.4)  G2: 77.9 (75.1 to 80.6)  Least Means (95% CI) Immediate posttreatment  G1: 52.9 (47.7 to 58.0)  G2: 60.1 (55.3 to 64.8)  G1 vs. G2, *P*=.01  3 mth FU G1: 49.7 (44.7 to 54.7)  G2: 56.0 (50.5 to 61.5)  G1 vs. G2, *P*=.047  6-month G1: 50.4 (45.0 to 55.8)  G2: 54.5 (49.3 to 59.7)  G1 vs. G2, p =.21  Treatment Effect, p=0.03  Treatment X Time, p=0.37 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Schnyder et al., 201185 | CAPS  Mean (SD) G1 Pre-tx: 78.6 (16.0) G1 Post-tx: 60.8 (32.8) G1 6 mth FU: 58.1 (30.5)  G2 Pre-tx: 73.4 (19.2) G2 Post-tx: 66.4 (20.0)  Group Effect, p<0.01 | NR | NR | NR |
| Simon et al., 200886 | NR | NR | NR | SPRINT Mean (SD) G1 Pre-tx: 16.11 (8.99) G1 Improvement Post-tx: 2.33 (5.24)  G2 Pre-tx: 17.00 (7.65) G2 Improvement Post-tx: 4.57 (7.24)  p=NS |
| Spence et al., 201187 | NR | NR | NR | NR |
| Stein et al., 200288 | CAPS Mean Change from Baseline (95% CI)  G1: -14.8 (SD=14.16) p<.05  G2 : -2.67 (SD=10.55) p<0.05 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Tarrier et al., 199989  Tarrier et al., 199990 | CAPS Global Severity Mean (SD) G1 Pre-tx: 71.14 (18.98)  G1 Post-tx: 48.24 (30.25) G1 6 mth FU: 52.11 (23.78)  G2 Pre-tx: 77.76 (14.95)  G2 Post-tx: 50.82 (23.99) G2 6 mth FU: 50.21 (24.37)  G1 vs. G2 differences, NS  12-Month Follow-up G1 Pre-tx: 71.76 (19.59) G1 12 mth FU: 45.16 (28.26)  G2 Pre-tx:76.93 (15.40) G2 12 mth FU: 52.48 (24.09)  G1 vs. G2 differences, NS | NR | NR | NR |
| Taylor et al., 200391 | CAPS  Data only reported in graphs  Completers  G1 Pre-Post changes, p<0.005 G2 Pre-Post changes, p<.001  G3 Pre-Post changes, p<0.005  Intent to Treat  No significant differences | NR | NR | NR |
| Tucker et al., 200192 | CAPS-2 Adjusted Mean Differences (95% CI), G1 vs. G2 -10.6 (-16.2 to -5.0) | NR | NR | TOP-8 Adjusted Mean Differences (95% CI), G1 vs. G2 -3.8 (-5.6 to -1.9) |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Tucker et al., 200393  Tucker et al., 200494 | Tucker et al., 2004 CAPS  Mean (SD) G1 Pre-tx: 91.0 (10.58)  G1 Post-tx: 60.28 (26.15)  G2 Pre-tx: 83.91 (17.28)  G2 Post-tx: 42.09 (29.09)  G3 Pre-tx: 94.20 (11.9) G3 Post-tx: 55.5 (29.07)  Between group differences, NS | NR | NR | NR |
| Tucker et al., 200795 | CAPS  Mean Percentage Change (SD) G1: -59.5 (35.9) G2: -45.5 (34.3) p=0.227 | NR | NR | TOP-8  Mean Percentage Change (SD) G1: -67.9 (30.0)  G2: -41.6 (37.8)  p= 0.023 |
| van der Kolk et al., 199496 | CAPS Difference in Improvement G1 vs. G2= 12.59  ANCOVA Results F = -12.59, t = -2.67, p=0.0106 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| van der Kolk et al., 200797 | CAPS  Mean (SD) ( Post-tx & FU - ITT)  G1 Pre-tx (1 mth CAPS): 71.7 (11.9)  G1 Pre-tx (1 wk CAPS): 69.4 (12.7)  G1 Post-tx: 32.55 (22.5)  G1 FU: 25.79 (21.61)  G2 Pre-tx (1 mth CAPS): 75.9 (15.6)  G2 Pre-tx (1 wk CAPS): 73.7 (13.4)  G2 Post-tx: 42.67 (22.11)  G2 FU: 42.12 (15.83)  G3 Pre-tx (1 mth CAPS): 74.5 (12.5)  G3 Pre-tx (1 wk CAPS): 70.3 (13.0)  G3 Post-tx: 43.55 (22.6)  G3 FU: NA  Posttreatment  Treatment effect, NS  G1 vs. G3, NS  G2 vs G3, NS  G1 vs. G2, NS  Followup  G1 vs. G2, p=0.005 |  |  |  |
| van Emmerik et al., 200898 | NR | NR | NR | NR |
| Yeh et al., 201199 | CAPS Mean( SD) G1 Pre-tx: 78.76 (12.64) G1 Post-tx: 30.41 (30.90)  G2 Pre-tx: 66.14 (22.63) G2 Post-tx: 35.78 (33.76)  Between Group Change, p=0.49 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered  CAPS or CAPS 2 | Clinician Administered  PSS-I | Clinician Administered  SI-PTSD | Clinician Administered  Other |
| Zlotnick et al., 2009100 | CAPS  Mean difference (95% CI)  -2.30 (-13.81, 9.21) | NR | NR | NR |
| Zohar et al., 2002101 | CAPS-2 Mean Change from Baseline (SD)  G1: -18.7 (6.7) G2: -13.5 (6.6) Between Group Change, p=0.530 | NR | NR | NR |

Abbreviations: ANOVA = analysis of variance; ANCOVA = analysis of covariance; CAPS = Clinician-administered PTSD Scale; CI = confidence interval; FU = follow-up; NR= not reported; NS = not significant; PSS= PTSD Symptom Scale; PSS-I= PTSD Symptom Scale Interview; Pre-tx = pretreatment; Post-tx = Posttreatment; PTSD= Post-Traumatic Stress Disorder; SD = standard deviation; SE = standard error; SI-PTSD or SIP= Structured Interview for PTSD; SPRINT=  Short PTSD Rating Interview; TOP-8 = Treatment Outcome PTSD Scale; SD = standard deviation; SE = standard error.